2.4.0.8036 - Disclosure - Organization and Nature of Business (Details)truefalsefalse1false USDtruefalseContext_Custom_15-Jan-2008_16-Jan-2008_BusinessAcquisitionAxis_ViscorpIncMemberhttp://www.sec.gov/CIK0001362718duration2008-01-15T00:00:002008-01-16T00:00:00falsefalseViscorp Inc. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ViscorpIncMemberus-gaap_BusinessAcquisitionAxisexplicitMembersharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170$2false truefalseContext_As_Of__30-Sep-2007_BusinessAcquisitionAxis_GrandwayGroupsHoldingsLtdMemberhttp://www.sec.gov/CIK0001362718instant2007-09-30T00:00:000001-01-01T00:00:00falsefalseGrandway Groups Holdings Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_GrandwayGroupsHoldingsLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberpureStandardhttp://www.xbrl.org/2003/instancepurexbrli03false USDtruefalse$Context_Custom_01-Nov-2012_30-Nov-2012_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718duration2012-11-01T00:00:002012-11-30T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$4false USDtruefalse$Context_Custom_01-Aug-2012_29-Aug-2012_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718duration2012-08-01T00:00:002012-08-29T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$5false CNYtruefalseContext_Custom_01-Aug-2012_29-Aug-2012_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718duration2012-08-01T00:00:002012-08-29T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberCNYStandardhttp://www.xbrl.org/2003/iso4217CNYiso42170pureStandardhttp://www.xbrl.org/2003/instancepurexbrli0CNYCNY6false USDtruefalse$Context_Custom_01-Jul-2009_30-Jul-2009_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718duration2009-07-01T00:00:002009-07-30T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false CNYtruefalseContext_Custom_01-Jul-2009_30-Jul-2009_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718duration2009-07-01T00:00:002009-07-30T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberCNYStandardhttp://www.xbrl.org/2003/iso4217CNYiso42170CNYCNY8false USDtruefalse$Context_As_Of__30-Jun-2013_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false truefalseContext_As_Of__30-Oct-2007_BusinessAcquisitionAxis_ChengduTianyinPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718instant2007-10-30T00:00:000001-01-01T00:00:00falsefalseChengdu Tianyin Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberpureStandardhttp://www.xbrl.org/2003/instancepurexbrli010false truefalseContext_Custom_01-Aug-2012_31-Aug-2012_BusinessAcquisitionAxis_ChengduTianyinMedicineTradingCoLtdMemberhttp://www.sec.gov/CIK0001362718duration2012-08-01T00:00:002012-08-31T00:00:00falsefalseChengdu Tianyin Medicine Trading Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_ChengduTianyinMedicineTradingCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberShareholderStandardhttp://www.tianyinpharma.com/20130630shareholdertpi011false USDtruefalse$Context_As_Of__31-Mar-2013_BusinessAcquisitionAxis_SichuanJiangchuanPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718instant2013-03-31T00:00:000001-01-01T00:00:00falsefalseSichuan Jiangchuan Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_SichuanJiangchuanPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12false USDtruefalse$Context_As_Of__21-Aug-2009_BusinessAcquisitionAxis_SichuanJiangchuanPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718instant2009-08-21T00:00:000001-01-01T00:00:00falsefalseSichuan Jiangchuan Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_SichuanJiangchuanPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberpureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13false CNYtruefalseContext_As_Of__21-Aug-2009_BusinessAcquisitionAxis_SichuanJiangchuanPharmaceuticalCoLtdMemberhttp://www.sec.gov/CIK0001362718instant2009-08-21T00:00:000001-01-01T00:00:00falsefalseSichuan Jiangchuan Pharmaceutical Co., Ltd. [Member]us-gaap_BusinessAcquisitionAxisxbrldihttp://xbrl.org/2006/xbrlditpi_SichuanJiangchuanPharmaceuticalCoLtdMemberus-gaap_BusinessAcquisitionAxisexplicitMemberCNYStandardhttp://www.xbrl.org/2003/iso4217CNYiso42170CNYCNY1true 4tpi_OrganizationAndNatureOfBusinessTextualAbstracttpi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Organization and Nature of Business (Textual)2false 5us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssuedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1279080012790800falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of equity interests issued or issuable to acquire entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479 false1Common stock issued in acquisition of Raygere Limited3false 5tpi_BusinessAcquisitionRatioOfSharesOfCommonStockExchangedToFacilitateReverseMergertpi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00One-to-one ratio.falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringBusiness acquisition ratio of shares of common stock exchanged to facilitate reverse merger.No definition available.false0Ratio common stock issued in exchanged of equity interest in Raygere4false 5us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquiredus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.001.00falsefalsefalse2truetruefalse1.001.00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalsenum:percentItemTypepurePercentage of voting equity interests acquired at the acquisition date in the business combination.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 false0Percentage of equity interest acquired in subsidiary5false 5tpi_BusinessAcquisitionPurchasePriceAllocationsAssetsAcquiredtpi_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to assets acquired.No definition available.false2Amount of assets Viscorp was delivered at time of closing6false 5tpi_BusinessAcquisitionPurchasePriceAllocationsLiabilitiesAssumedtpi_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to liabilities assumed.No definition available.false2Amount of liabilities Viscorp was delivered at time of closing7false 5tpi_BusinessCombinationIndirectWhollyOwnedSubsidiaryEquityInterestInSubsidiaryPercentagetpi_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9truetruefalse1.001.00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalsenum:percentItemTypepureBusiness combination indirect wholly owned subsidiary equity interest in subsidiary percentage.No definition available.false0Percentage of interest acquired in an indirect wholly owned subsidiary8false 5tpi_BusinessEstablishmentCostForSalesAndDistributionOfMedicineIncurredBySubsidiarytpi_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse700000700000falsefalsefalse7truefalsefalse50000005000000falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryBusiness establishment cost for sales and distribution of medicine incurred by subsidiary.No definition available.false2Cost incurred to establish a wholly-owned trading subsidiary for sales and distribution of medicine9false 5tpi_RegisteredCapitalOfSubsidiarytpi_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse32000003200000falsefalsefalse12truefalsefalse32000003200000falsefalsefalse13truefalsefalse2000000020000000falsefalsefalsexbrli:monetaryItemTypemonetaryRegistered capital of subsidiary.No definition available.false2Registered capital of subsidiary10false 5tpi_PercentageOfRegisteredCapitalAccountedBySubsidiarytpi_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12truetruefalse0.870.87falsefalsefalse13truetruefalse0.870.87falsefalsefalsenum:percentItemTypepurePercentage of accounted capital of subsidiary.No definition available.false0Percentage of registered capital accounted by subsidiary11false 5tpi_NumberOfExistingShareholdersEnteredIntoShareTransferAgreementWithCompanytpi_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse22falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerNumber of existing shareholders entered into share transfer agreement with the company.No definition available.false256Number of existing shareholders entered into share transfer agreement with the company12false 5us-gaap_EquityMethodInvestmentOwnershipPercentageus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3truetruefalse1.001.00falsefalsefalse4truetruefalse1.001.00falsefalsefalse5truetruefalse1.001.00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalsenum:percentItemTypepureThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 false0Ownership percentage owned13false 5us-gaap_PaymentsToAcquireBusinessesGrossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse210600210600falsefalsefalse4truefalsefalse210600210600falsefalsefalse5truefalsefalse13000001300000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 false2Total purchase consideration of acquired entity14false 5tpi_BusinessAcquisitionPurchasePriceAllocationsGoodwillAmounttpi_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse210600210600USD$falsetruefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of goodwill arising from a business combination, which is the excess of the cost of the acquired entity over the amounts assigned to assets acquired and liabilities assumed.No definition available.false2Purchase price allocated to goodwillfalseOrganization and Nature of Business (Details)NoRoundingNoRoundingUnKnownUnKnowntruefalsetrueSheethttp://www.tianyinpharma.com/role/OrganizationandNatureofBusinessDetails1314